In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as skin, lung, or bone and soft tissue cancer (sarcomas), they have not yet proven themselves as a treatment method. Tumor shrinkage was achieved only in rare cases, but the side effects were all the more severe. An international research group led by scientists from the National Center for Tumor Diseases (NCT/UCC) in Dresden has now succeeded for the first time in a phase 1 clinical trial in testing a novel cell therapy approach that also shows promise for solid tumors. The results were now published in the renowned journal Nature Medicine.

A colon cancer screening program that offered flexible options doubled colorectal cancer screening rates, cut cancer incidence by a third, halved deaths, and brought racial differences in outcomes to nearly zero, according to a study to be presented at Digestive Disease Week (DDW) 2025.

An interdisciplinary research team from the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), the InnoHK Laboratory of Data Discovery for Health (InnoHK D24H), and the London School of Hygiene & Tropical Medicine (LSHTM) has unveiled the world’s first artificial intelligence (AI) model designed to classify both the cancer stage and risk category of thyroid cancer, achieving impressive accuracy exceeding 90%. This innovative HKUMed AI model promises to significantly cut frontline clinicians’ pre-consultation preparation time by approximately 50%, aligning with the HKSAR Government’s initiative to harness AI technology in healthcare. The findings were published in the journal npj Digital Medicine.

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new study led by City of Hope researchers.